company background image
A205

Humasis KOSDAQ:A205470 Stock Report

Last Price

₩13.50k

Market Cap

₩461.6b

7D

13.0%

1Y

-25.0%

Updated

12 May, 2022

Data

Company Financials
A205470 fundamental analysis
Snowflake Score
Valuation5/6
Future Growth0/6
Past Performance4/6
Financial Health6/6
Dividends3/6

A205470 Stock Overview

Humasis Co. Ltd. develops, manufactures, and markets in-vitro diagnostics for the detection of cardiac marker, fertility hormone, infectious disease, tumor marker, and cotinine for home and laboratory use in South Korea and internationally.

Humasis Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Humasis
Historical stock prices
Current Share Price₩13,500.00
52 Week High₩36,450.00
52 Week Low₩11,300.00
Beta-0.66
1 Month Change-12.05%
3 Month Change-45.34%
1 Year Change-25.00%
3 Year Change718.18%
5 Year Changen/a
Change since IPO608.66%

Recent News & Updates

Shareholder Returns

A205470KR Medical EquipmentKR Market
7D13.0%-3.4%-3.3%
1Y-25.0%-7.5%-14.3%

Return vs Industry: A205470 underperformed the KR Medical Equipment industry which returned -7.5% over the past year.

Return vs Market: A205470 underperformed the KR Market which returned -14.3% over the past year.

Price Volatility

Is A205470's price volatile compared to industry and market?
A205470 volatility
A205470 Average Weekly Movement8.9%
Medical Equipment Industry Average Movement5.7%
Market Average Movement5.5%
10% most volatile stocks in KR Market10.4%
10% least volatile stocks in KR Market3.1%

Stable Share Price: A205470 is more volatile than 75% of KR stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: A205470's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of KR stocks.

About the Company

FoundedEmployeesCEOWebsite
2000117Jeong-Hak Chahttps://www.humasis.com

Humasis Co. Ltd. develops, manufactures, and markets in-vitro diagnostics for the detection of cardiac marker, fertility hormone, infectious disease, tumor marker, and cotinine for home and laboratory use in South Korea and internationally. It offers pregnancy and ovulation self-test products; Hubi-Quan Pro, a self-contained and cartridge reader to provide rapid quantitative results for membrane-based lateral flow immunochromatographic assays; and various rapid test kits. The company was founded in 2000 and is based in Anyang, South Korea.

Humasis Fundamentals Summary

How do Humasis's earnings and revenue compare to its market cap?
A205470 fundamental statistics
Market Cap₩461.62b
Earnings (TTM)₩151.20b
Revenue (TTM)₩321.83b

3.1x

P/E Ratio

1.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
A205470 income statement (TTM)
Revenue₩321.83b
Cost of Revenue₩111.61b
Gross Profit₩210.22b
Other Expenses₩59.02b
Earnings₩151.20b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)4.42k
Gross Margin65.32%
Net Profit Margin46.98%
Debt/Equity Ratio0%

How did A205470 perform over the long term?

See historical performance and comparison

Dividends

1.5%

Current Dividend Yield

5%

Payout Ratio

Valuation

Is Humasis undervalued compared to its fair value and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: A205470 (₩13500) is trading below our estimate of fair value (₩1254481.07)

Significantly Below Fair Value: A205470 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: A205470 is good value based on its PE Ratio (3.1x) compared to the KR Medical Equipment industry average (12.6x).

PE vs Market: A205470 is good value based on its PE Ratio (3.1x) compared to the KR market (14x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate A205470's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: A205470 is good value based on its PB Ratio (2.3x) compared to the KR Medical Equipment industry average (2.4x).


Future Growth

How is Humasis forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


5.9%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Humasis has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Humasis performed over the past 5 years?

Past Performance Score

4/6

Past Performance Score 4/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


622.2%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: A205470 has high quality earnings.

Growing Profit Margin: A205470's current net profit margins (47%) are higher than last year (45.8%).


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if A205470's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare A205470's past year earnings growth to its 5-year average.

Earnings vs Industry: A205470 earnings growth over the past year (622.2%) exceeded the Medical Equipment industry 30.5%.


Return on Equity

High ROE: A205470's Return on Equity (74.9%) is considered outstanding.


Financial Health

How is Humasis's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: A205470's short term assets (₩294.6B) exceed its short term liabilities (₩135.5B).

Long Term Liabilities: A205470's short term assets (₩294.6B) exceed its long term liabilities (₩3.2B).


Debt to Equity History and Analysis

Debt Level: A205470 is debt free.

Reducing Debt: A205470 had no debt 5 years ago.

Debt Coverage: A205470 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: A205470 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Humasis's current dividend yield, its reliability and sustainability?

Dividend Score

2/6

Dividend Score 2/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


1.48%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: A205470's dividend (1.48%) is higher than the bottom 25% of dividend payers in the KR market (0.85%).

High Dividend: A205470's dividend (1.48%) is low compared to the top 25% of dividend payers in the KR market (2.72%).


Stability and Growth of Payments

Stable Dividend: Too early to tell whether A205470's dividend payments have been stable as they only just started paying a dividend.

Growing Dividend: Too early to tell if A205470's dividend payments are increasing as they only just started paying a dividend.


Earnings Payout to Shareholders

Earnings Coverage: With its low payout ratio (4.5%), A205470's dividend payments are thoroughly covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its low cash payout ratio (3.7%), A205470's dividend payments are thoroughly covered by cash flows.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Jeong-Hak Cha

no data

Tenure

Jeong-Hak Cha is Chief Executive Officer of Humasis Co. Ltd.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Humasis Co. Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: Humasis Co. Ltd.
  • Ticker: A205470
  • Exchange: KOSDAQ
  • Founded: 2000
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Implied Market Cap: ₩461.620b
  • Shares outstanding: 34.19m
  • Website: https://www.humasis.com

Number of Employees


Location

  • Humasis Co. Ltd.
  • 37, Gunpocheomdansaneop 2-ro
  • Gunpo-si
  • Gyeonggi-do
  • 15880
  • South Korea

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/12 00:00
End of Day Share Price2022/05/12 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.